Patents by Inventor Qimin Chao
Qimin Chao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10023632Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: GrantFiled: July 18, 2016Date of Patent: July 17, 2018Assignee: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Wolfgang Ebel, Jian Li, Qimin Chao, Eric Routhier
-
Publication number: 20160333089Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: ApplicationFiled: July 18, 2016Publication date: November 17, 2016Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Wolfgang Ebel, Jian Li, Qimin Chao, Eric Routhier
-
Patent number: 9422367Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: GrantFiled: November 26, 2013Date of Patent: August 23, 2016Assignee: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Publication number: 20140086928Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: ApplicationFiled: November 26, 2013Publication date: March 27, 2014Applicant: MORPHOTEK, INC.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Patent number: 8623364Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: GrantFiled: October 24, 2012Date of Patent: January 7, 2014Assignee: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Publication number: 20130058945Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: ApplicationFiled: October 24, 2012Publication date: March 7, 2013Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Patent number: 8318168Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: GrantFiled: April 16, 2010Date of Patent: November 27, 2012Assignee: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Publication number: 20120207771Abstract: The present invention provides methods and kits for assessing whether a subject is afflicted with an FR?-expressing cancer, methods and kits for predicting the progression of ovarian cancer in a subject afflicted with an FR?-expressing cancer, methods and kits for assessing the level of risk that a subject will develop an FR?-expressing cancer, and methods of stratifying a subject with an FR?-expressing cancer into cancer therapy groups. The methods involve determining the level of folate receptor alpha (FR?) which is not bound to a cell in a sample derived from the subject and comparing this level with the level of FR? in a control sample.Type: ApplicationFiled: November 4, 2011Publication date: August 16, 2012Applicant: Morphotek Inc.Inventors: Daniel J. O'Shannessy, Luigi Grasso, Shanhong Wan, Qimin Chao, Elizabeth Brooke Somers
-
Publication number: 20100272730Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: ApplicationFiled: April 16, 2010Publication date: October 28, 2010Applicant: MORPHOTEK, INC.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Patent number: 7741450Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: GrantFiled: February 8, 2007Date of Patent: June 22, 2010Assignee: Morphotek Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Publication number: 20080292641Abstract: Hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity, particularly neutralizing activity against granulocyte-macrophage colony stimulating factor, and methods of generating the hybridoma lines are provided. Target antigens and epitopes are also provided. The antibodies may be used in therapeutic methods, for example in the treatment of cancer, infectious disease, or autoimmune disease.Type: ApplicationFiled: February 8, 2007Publication date: November 27, 2008Applicant: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Jian Li, Qimin Chao, Eric Routhier, Wolfgang Ebel
-
Publication number: 20080131427Abstract: Whole Genome Evolution Technology can be considered a broad tool for supporting the needs for scaleable manufacturing of therapeutic antibodies. Its random nature and in vivo mode of action separate this process from other complementary technologies, thus providing alternative solutions to improve a host cell's manufacturing performance. The speed with which a pre-existing production strain can be optimized makes this process suitable for satisfying the current need for rapid cell line optimization to produce faster growing cells exhibiting high titers of antibody at the preclinical, clinical or commercialization stage.Type: ApplicationFiled: April 16, 2007Publication date: June 5, 2008Applicant: Morphotek, Inc.Inventors: J. Bradford Kline, Qimin Chao, Philip M. Sass, Luigi Grasso, Nicholas C. Nicolaides
-
Publication number: 20030143586Abstract: The invention provides methods for identifying polymorphic markers for herbicide resistance in weeds and for generating herbicide susceptible and herbicide resistant weeds by mutagenizing weeds and comparing genetic differences between herbicide resistant and herbicide susceptible weeds. The methods may involve the inhibition of mismatch repair in the weeds through the introduction of dominant negative alleles of mismatch repair genes, through T-DNA insertional mutations, or the use of chemical inhibitors of mismatch repair. The invention also provides polymorphic markers of herbicide resistance and methods and kits to screen for herbicide resistant weeds, such as horseweed, goosegrass and rye grass.Type: ApplicationFiled: October 11, 2002Publication date: July 31, 2003Inventors: Qimin Chao, Luigi Grasso, Nicholas C. Nicolaides, Philip M. Sass